Anand Rathi: Indian Pharmaceutical Market Growth Reprises Positive Territory, Industry Grows 2.4% In June
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
After a steep decline in the previous two months, Indian pharmaceutical market growth bounced back in June 20, on expected lines. The industry grew 2.4% overall, a strong rebound after declining 11% in April and 9% in May. Q1 FY21 IPM sales were, however, down 6% due to lack of volume growth. For the quarter, industry volumes were down 12% though softened by 5% price growth, and launches aided 1% growth.
The domestic pharma market in FY21 is expected to still grow in single digits in spite of such as muted Q1. Growth in the sector is rebounding as the economy is opening up and moving toward pre-Covid-19 levels. We expect pharma to be one of the fastest growing industries in India as it is still hiking prices 4.5% in Q1 FY21. We expect volume growth to recover from June levels as there may be an increase in number of prescriptions dispensed and in surgeries in the last part of the current fiscal (once the lockdown is fully lifted). In the current context we expect swift recovery in multinational corporation (MNC) pharma companies like Abbott, Pfizer and AstraZeneca, while the domestic range of select Indian companies such as Torrent, Sun, Lupin, Ipca (higher share of sales in chronic therapies) is expected to outperform the market in FY21.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.